Efficacy Studies in Xenograft and Syngeneic Cancer Models in Mice
Our Oncology program for evaluation of test compounds in xenograft and syngeneic tumor models in mice offers a unique suite of technologies, scientific expertise and technical skills for monitoring of primary and metastatic tumor growth in vivo:
- Years of experience in the field of Oncology and Immune Oncology
- Sophisticated surgery techniques for orthotopic tumor implantation and primary tumor excision
- Experience with xenograft tumor models in humanized mice
- Advanced expertise in FACS analysis of tumor infiltrating lymphocytes
- Pioneers in biophotonic imaging for tracking orthotopic and metastatic tumor growth
- Biochemical capabilities for multiplex analyses of cytokines, hormones and other analytes
- Multidisciplinary scientific team with extensive experience in evaluation of a broad range of compounds and biologics in efficacy studies
Each study is custom-designed to best meet individual client needs. Interpretive data analysis and summary reports are provided at the completion of each study.
Cell line-derived xenograft (CDX) models that utilize patient-derived tumor cells can provide a more individualized platform for immune-oncology research. CDX models establish a tumor-bearing system in vivo by implanting immunocompromised mice with cell lines derived from primary tumor tissue. They are an attractive preclinical tool as the xenotransplantation of human cell lines is easy to control, well established and allows for rapid evaluation of therapeutic agents. The molecular profiles of CDXs demonstrate broad similarity when compared to the primary tumor. Most importantly, from a pharmacological perspective, the response of CDXs to standard chemotherapies often recapitulates the donor patient’s response to the same treatment. Therefore, CDXs can complement tumor biopsies and PDXs and can be a source of tumor material for research purposes. CDXs offer an opportunity to generate tailored treatment regimens for those patients that cannot undergo surgery or an alternative invasive procedure.
All of our well-characterized CDX models include select molecular and clinical tumor data. Models include, but are not limited to:
- B-cell line EBV-EBNA1 positive
- B-Cell non-Hodgkin Lymphoma
- B-Cell plasmacytoma
- Breast adenocarcinoma
- Breast adenocarcinoma, metastatic
- Breast invasive ductal carcinoma, stage IIA, grade 3
- Breast normal mammary gland
- Burkitt’s Lymphoma
- Cervix adenocarcinoma
- Cervix squamous cell carcinoma
- Clear cell renal cell carcinoma, CCRCC
- Colon adenocarcinoma
- Colon adenocarcinoma (KRAS mutated)
- Colon adenocarcinoma (KRAS normal)
- Colorectal carcinoma
- Epidermoid carcinoma
- Head and neck squamous cell carcinoma
- HeLa derivative
- Lung cancer, NSCLC
- Lung non-small cell carcinoma, NSCLC
- Bronchioalveolar carcinoma
- Lung non-small cell carcinoma, NSCLC, large cell Adenocarcinoma
- Lung small cell carcinoma, SCLC
- Neuroblastoma
- Normal foreskin fibroblasts
- Ovarian carcinoma
- Ovarian teratocarcinoma
- Pancreatic ductal adenocarcinoma, PDAC
- Prostate carcinoma metastatic
- T-cell leukemia acute
- Acute lymphoblastic leukemia, T-ALL
- Urinary bladder carcinoma, grade II
- Urinary bladder transitional cell carcinoma
- Uterine carcinoma
Small Animal Radiation Research Platform
GD3 offers a Small Animal Radiation Research Platform (SARRP) utilizing Xstrahl Life Sciences industry-leading SARRP image-guided micro irradiator. This powerful technology incorporates high resolution CT imaging with precise radiation delivery to enable researchers to pinpoint an exact anatomical target and more efficiently and effectively incorporate irradiation into their immuno-oncology study designs.
In Vivo Preclinical Imaging Platform Key Features:
- Fully CT-guided irradiation device
- Tumor targeted or whole body irradiation
- Noninvasive, precise and accurate
- Radiotherapy application in small animal models
- Ideal for studying radiotherapy with immunotherapy to mimic ongoing clinical trials
Image of a Tumor Targeted/Focal Radiology
SARRP is a customizable research platform designed to provide our preclinical research community with the ability to engage in the most clinically relevant, reproducible, and technically advanced studies. SARRP delivers image-guided targeted irradiations as individual or combined beams defined by brass collimators which directs a precise radiation delivery to a small circular, square, or rectangular fields.
At GD3, advances in the understanding of the molecular biology of cancer, combined with rapid technological advances in radiation therapy, targeting, and delivery, are maintaining the need for more research to study radiation effects in complex systems.
Each radiation therapy study is custom-designed to best meet individual client needs. Interpretive data analysis and summary reports are provided at the completion of each study.
